| 摘要 |
<p>The present invention concerns the use of various forms of GIP-receptor antagonists to attenuate the insulin response to GIP following meals in animals, such as humans, to prevent, reduce, inhibit and/or treat nonalcoholic fatty liver disease by virtue of its prevention and/or reversal of hyperinsulinemia and insulin resistance. Thus, the use of the GIP-receptor antagonists in any effective form is believed to prevent the development and reverse the process of NAFLD. The present invention is accomplished by administering an effective amount of an antagonistic agent, such as a GIP antagonist or an antisense molecule, to antagonize, block, inhibit or ablate the receptor to Glucose-Dependent Insulinotropic Polypeptide (GIP).</p> |
